Sangamo Therapeutics, Inc. (SGMO) financial statements (2022 and earlier)
Company profile
| Business Address |
7000 MARINA BLVD BRISBANE, CA 94005 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 641 | 362 | 400 | 243 | 143 | 209 | 179 | ||
| Cash and cash equivalents | 131 | 80 | 140 | 50 | 22 | 69 | 6 | ||
| Short-term investments | 510 | 282 | 260 | 193 | 120 | 140 | 173 | ||
| Restricted cash and investments | 0 | ||||||||
| Receivables | 6 | 38 | 5 | 4 | 5 | 3 | 11 | ||
| Prepaid expense | 2 | 1 | 1 | ||||||
| Other current assets | 0 | ||||||||
| Other undisclosed current assets | 12 | 5 | 5 | 2 | |||||
| Total current assets: | 660 | 405 | 411 | 248 | 150 | 213 | 191 | ||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 71 | ✕ | ✕ | ✕ | ✕ | ✕ | |||
| Property, plant and equipment | 41 | 30 | 79 | 31 | 7 | 3 | 1 | ||
| Long-term investments and receivables | 51 | 22 | 1 | 47 | |||||
| Long-term investments | 51 | 22 | 1 | 47 | |||||
| Intangible assets, net (including goodwill), including: | 101 | 92 | 95 | 2 | 2 | 2 | 3 | ||
| Goodwill | 43 | 39 | 40 | 2 | 2 | 2 | |||
| Intangible assets, net (excluding goodwill) | 58 | 53 | 55 | 2 | |||||
| Other undisclosed intangible assets, net (including goodwill) | 2 | ||||||||
| Restricted cash and investments | 2 | 2 | 4 | ||||||
| Other noncurrent assets | 14 | 9 | 3 | 5 | 0 | 0 | 0 | ||
| Other undisclosed noncurrent assets | 77 | ||||||||
| Total noncurrent assets: | 279 | 232 | 180 | 38 | 8 | 5 | 52 | ||
| TOTAL ASSETS: | 939 | 638 | 590 | 287 | 158 | 217 | 243 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 52 | 18 | 21 | 11 | 6 | 8 | 9 | ||
| Accounts payable | 13 | 7 | 3 | 0 | 3 | 4 | 6 | ||
| Accrued liabilities | 19 | 1 | 2 | 1 | 0 | 0 | 1 | ||
| Employee-related liabilities | 21 | 9 | 5 | 3 | 3 | 3 | |||
| Other undisclosed accounts payable and accrued liabilities | 10 | 7 | 4 | 1 | 1 | (0) | |||
| Deferred revenue | 92 | ✕ | ✕ | ✕ | ✕ | ✕ | |||
| Deferred revenue and credits | ✕ | ✕ | ✕ | 28 | 4 | 9 | 9 | ||
| Contract with customer, liability | ✕ | 39 | 48 | ✕ | ✕ | ✕ | ✕ | ||
| Other undisclosed current liabilities | 14 | 9 | 5 | 3 | 3 | 3 | |||
| Total current liabilities: | 144 | 70 | 79 | 45 | 13 | 20 | 21 | ||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 38 | ||||||||
| Operating lease, liability | 38 | ✕ | ✕ | ✕ | ✕ | ✕ | |||
| Liabilities, other than long-term debt | 259 | 94 | 117 | 29 | 4 | 5 | 16 | ||
| Deferred revenue and credits | ✕ | ✕ | ✕ | 29 | 4 | 5 | 13 | ||
| Deferred revenue | 245 | ✕ | ✕ | ✕ | ✕ | ✕ | |||
| Contract with customer, liability | ✕ | 81 | 108 | ✕ | ✕ | ✕ | ✕ | ||
| Deferred tax liabilities, net | ✕ | 7 | 7 | 1 | |||||
| Deferred income tax liabilities | 7 | ✕ | ✕ | ✕ | ✕ | ✕ | |||
| Other liabilities | 7 | 6 | 2 | ||||||
| Business combination, contingent consideration, liability | 2 | ||||||||
| Other undisclosed noncurrent liabilities | 41 | 28 | 25 | 4 | |||||
| Total noncurrent liabilities: | 298 | 135 | 145 | 54 | 8 | 5 | 16 | ||
| Total liabilities: | 441 | 205 | 223 | 99 | 22 | 25 | 37 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent | 498 | 433 | 367 | 188 | 136 | 192 | 207 | ||
| Common stock | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||
| Additional paid in capital | 1,269 | 1,091 | 930 | 683 | 576 | 561 | 535 | ||
| Accumulated other comprehensive income (loss) | 5 | (2) | (1) | (0) | 0 | (0) | |||
| Accumulated deficit | (778) | (657) | (563) | (495) | (441) | (369) | (329) | ||
| Stockholders' equity attributable to noncontrolling interest | (1) | 0 | 1 | ||||||
| Total stockholders' equity: | 497 | 433 | 367 | 188 | 136 | 192 | 207 | ||
| TOTAL LIABILITIES AND EQUITY: | 939 | 638 | 590 | 287 | 158 | 217 | 243 | ||
Income statement (P&L) ($ in millions)
| 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | ||
|---|---|---|---|---|---|---|---|---|
| Gross profit: | 118 | 102 | 84 | 37 | 19 | 40 | 46 | |
| Operating expenses | (248) | (208) | (162) | (93) | (92) | (86) | (73) | |
| Operating loss: | (130) | (105) | (77) | (56) | (73) | (47) | (27) | |
| Nonoperating income | 1 | 0 | 0 | |||||
| Other nonoperating income | 1 | 0 | ||||||
| Loss from continuing operations before equity method investments, income taxes: | (130) | (105) | (77) | (56) | (72) | (46) | (26) | |
| Other undisclosed income from continuing operations before income taxes | 9 | 10 | 8 | 2 | ||||
| Loss from continuing operations before income taxes: | (121) | (95) | (69) | (55) | (72) | (46) | (26) | |
| Income tax expense (benefit) | (0) | 0 | 6 | |||||
| Net loss: | (121) | (95) | (69) | (55) | (72) | (41) | (26) | |
| Net income attributable to noncontrolling interest | 0 | 0 | 1 | |||||
| Net loss available to common stockholders, diluted: | (121) | (95) | (68) | (55) | (72) | (41) | (26) | |
Comprehensive Income ($ in millions)
| 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (121) | (95) | (69) | (55) | (72) | (41) | (26) | |
| Other comprehensive income (loss) | 8 | (2) | (1) | |||||
| Other undisclosed comprehensive income (loss) | (0) | 1 | (0) | |||||
| Comprehensive loss: | (113) | (96) | (70) | (55) | (72) | (41) | (26) | |
| Comprehensive income, net of tax, attributable to noncontrolling interest | 0 | 0 | 1 | |||||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (0) | 0 | 0 | (0) | ||||
| Comprehensive loss, net of tax, attributable to parent: | (113) | (96) | (69) | (55) | (72) | (41) | (26) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.